Meeting
2012 ASCO Annual Meeting
Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results.
Authors
Madhur Garg
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Madhur Garg , Jeanette Y Lee , Lisa A. Kachnic , Paul J. Catalano , David H. Henry , Timothy Patrick Cooley , Lee Ratner , William Wachsman , David Michael Aboulafia , Al Bowen Benson , Joel Palefsky , Richard Whittington , Ronald T. Mitsuyasu , Joseph A. Sparano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Anal Cancer
Clinical Trial Registration Number
NCT00316888 and NCT00324415
Citation
J Clin Oncol 30, 2012 (suppl; abstr 4030)
DOI
10.1200/jco.2012.30.15_suppl.4030
Abstract #
4030
Poster Bd #
22
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase II study of panitumumab, 5-fluorouracil, mitomycin-c and radiotherapy treatment in patients with non-metastatic squamous cell carcinoma of the anal canal: safety and efficacy results (VITAL study)—GEMCAD 09-02.
First Author: Jaime Feliu
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.
First Author: Ulrich Keilholz
Poster
2016 ASCO Annual Meeting
Phase II trials of cetuximab plus combined modality therapy (CMT) in squamous cell carcinoma of the anal canal (SCCAC) with and without human immunodeficiency virus (HIV) infection.
First Author: Madhur Garg